Adrenoleukodystrophy: Types, symptoms, inheritance, and more

If your body were a city, your cells would have tiny waste-management teams working 24/7. One of those teams lives in
structures called peroxisomes, and their job is to break down certain fatsespecially
very long-chain fatty acids (VLCFAs). In adrenoleukodystrophy (ALD), that system doesn’t
work the way it should, so VLCFAs build up andover timecan damage the brain’s white matter (myelin) and the adrenal
glands. That’s the serious part.

The “human” part is just as real: families notice a kid struggling in school, adults chalk up leg stiffness to “getting
older,” or someone winds up in the ER with an adrenal crisis that seems to come out of nowhere. ALD can be sneaky,
unpredictable, and unfair. But there’s also good news: newborn screening, earlier diagnosis, careful
monitoring, and targeted treatments for certain forms (including transplant and gene therapy in specific cases) have changed
what “possible” looks like.

What is adrenoleukodystrophy (ALD)?

ALD is a group of closely related disordersmost commonly X-linked adrenoleukodystrophy (X-ALD)caused by
changes (pathogenic variants) in the ABCD1 gene. The ABCD1 gene helps make a protein (often called ALDP)
that moves VLCFAs into peroxisomes so they can be broken down. When that transport system fails, VLCFAs accumulate in the
body, especially affecting the nervous system and adrenal glands.

Here’s the key twist: people with the same ABCD1 varianteven within the same familycan develop very different ALD “types”
(also called phenotypes). In other words, the gene change tells you the diagnosis, but it doesn’t reliably tell you which
form will show up, when it will begin, or how fast it will progress.

Types of ALD (phenotypes): the “same diagnosis, different story” problem

ALD is often grouped into a few major categories based on how it shows up clinically. The categories below are commonly used
in U.S. medical resources and reflect how doctors think about monitoring and treatment decisions.

1) Childhood cerebral ALD (often ages ~4–8 at onset)

This is the form many people have heard of because it can progress rapidly. “Cerebral” means it affects the brain, and the
damage involves inflammatory demyelination (loss of myelin). Early symptoms can look like behavioral or learning problems
before more obvious neurological signs appear.

2) Adrenomyeloneuropathy (AMN) (often adult onset)

AMN is typically a slower, progressive condition affecting the spinal cord and peripheral nerves. It often shows up in
adulthood (commonly in the 20s or later). Many people with AMN develop stiffness and weakness in the legs, balance problems,
and bladder issues. Some can also develop cerebral disease.

3) Addison-only phenotype (primary adrenal insufficiency)

Some individualsespecially malesmay first present with adrenal gland failure (Addison disease) with few or no neurological
symptoms at the beginning. This matters because adrenal insufficiency is treatable, but it can be life-threatening if missed.

4) Adult cerebral ALD

Cerebral inflammatory disease isn’t exclusive to children. Some adults develop cerebral ALD, which can involve cognitive and
psychiatric symptoms alongside neurological decline.

5) Symptomatic females with an ABCD1 variant

Females who carry an ABCD1 pathogenic variant are often symptom-free in childhood, but many can develop neurologic symptoms in
adulthoodoften AMN-like (for example, leg stiffness, walking difficulty, and neuropathy). Adrenal insufficiency is less common
in females than in affected males, but evaluation is individualized.

Symptoms: what ALD can look like in real life

ALD symptoms vary by type and by person. Still, there are patterns worth knowingespecially the early “red flags” that can
prompt testing.

Brain and nervous system symptoms (especially in cerebral ALD)

• Behavior or school changes: attention issues, new impulsivity, declining grades, trouble understanding spoken language.
• Sensory changes: vision problems, hearing loss.
• Neurological progression: loss of coordination, trouble walking, spasticity, swallowing difficulty.
• Seizures may occur as the disease advances.

Spinal cord and peripheral nerve symptoms (common in AMN)

• Leg stiffness (spasticity), weakness, and fatigue with walking.
• Balance issues and frequent tripping.
• Bladder dysfunction: urgency, frequency, incontinence.
• Sexual dysfunction can occur.
• Pain (neuropathic pain) or numbness/tingling may develop.

Adrenal insufficiency symptoms (Addison disease)

The adrenal glands produce hormones that help regulate blood pressure, stress response, blood sugar, and salt balance. When
they fail, symptoms may include:

• Unusual fatigue, weakness, dizziness (especially when standing)
• Weight loss, poor appetite, nausea/vomiting
• Low blood pressure
• Skin darkening (hyperpigmentation) in some cases
• Adrenal crisis risk during illness or stress (a medical emergency)

How ALD is diagnosed

Diagnosis usually combines biochemical testing, genetic testing, imaging, and endocrine evaluation. Many U.S. states now
identify ALD risk through newborn screening, which can lead to confirmatory testing before symptoms start.

Newborn screening (why timing can change everything)

Newborn screening doesn’t “diagnose” ALD by itself, but it can flag a baby for further evaluation. Screening programs often
look for markers related to VLCFA metabolism (commonly a specialized lipid marker in dried blood spots), then confirm with
follow-up testing.

Blood tests: VLCFAs and adrenal hormones

• VLCFA levels in plasma are a classic biochemical clue, especially in males.
• Adrenal function testing may include cortisol and ACTH (and sometimes stimulation testing) to detect early adrenal insufficiency.

Genetic testing: ABCD1 confirmation

Identifying an ABCD1 pathogenic variant confirms X-ALD and helps guide family testing. It’s also crucial for
cascade screening of relativesbecause diagnosing someone early can prevent a life-threatening adrenal crisis and allows close
monitoring for cerebral disease.

Brain MRI: watching for early cerebral disease

MRI can detect cerebral changes before symptoms become obvious. Specialists may use scoring systems (such as the
Loes score) and look for signs of active inflammation (often described as contrast enhancement) to determine
whether targeted therapy may be appropriate. Because treatment outcomes depend heavily on timing, MRI surveillance schedules
can be very specific for at-risk boys identified through newborn screening.

Inheritance: how ALD is passed down

X-ALD is inherited in an X-linked pattern. That means the ABCD1 gene sits on the X chromosome.

If the mother carries an ABCD1 pathogenic variant

• Each pregnancy has a 50% chance the child inherits the variant.
• Sons who inherit it are typically affected (because they have one X chromosome).
• Daughters who inherit it are typically carriers and may develop symptoms later in life.

If the father is affected

• He will pass the variant to all daughters (they inherit his X chromosome).
• He will pass it to no sons (sons inherit his Y chromosome).

New (de novo) variants

Not every case is inherited. A portion of individuals have a de novo ABCD1 variant (a new change that occurs
spontaneously). This is one reason ALD can appear in a family “out of the blue.”

Family planning options

Families may consider genetic counseling, targeted testing of relatives, anddepending on personal values and circumstances
options such as prenatal testing or preimplantation genetic testing. The right choice is individual, and counseling should be
nonjudgmental and practical.

Treatment and management: what can actually be done?

ALD treatment depends on the type and stage of disease. Some interventions aim to prevent emergencies (like adrenal crisis),
some aim to slow or halt cerebral progression (when caught early), and others focus on symptom management and quality of life.

Adrenal insufficiency: highly treatable (and important to catch)

If adrenal insufficiency is present, doctors typically treat with corticosteroid replacement (and sometimes
additional hormone replacement depending on the specific deficiency). Families are often taught “stress dosing” during illness
and may carry emergency medication. This isn’t optionalit’s the seatbelt, airbag, and smoke detector all in one.

Surveillance: the “monitoring plan” is part of treatment

For boys identified through newborn screening, many specialty protocols emphasize:

• Regular adrenal testing (because failure can appear before neurologic symptoms).
• Scheduled brain MRIs to detect early cerebral changes when treatment is most effective.

A commonly cited surveillance approach includes MRIs at specific early-childhood intervals followed by frequent imaging through
childhood, then less frequent imaging laterbecause the window for early cerebral treatment is time-sensitive.

Cerebral ALD (early stage): transplant and gene therapy

When cerebral ALD is detected earlyoften before severe neurological symptomsspecialized centers may consider
therapies designed to slow or halt progression:

• Allogeneic hematopoietic stem cell transplant (HSCT) (commonly discussed as bone marrow or stem cell transplant) has
  long been a key option for early-stage cerebral ALD.
• Autologous gene therapy (elivaldogene autotemcel, SKYSONA) is FDA-approved for a specific group:
  boys ages 4–17 with early, active cerebral ALD who do not have an available HLA-matched donor for allogeneic HSCT.

Important reality check: these treatments are not casual or simple. They require expert evaluation, careful staging, and an
honest discussion of risks and benefits. For example, SKYSONA carries serious safety warnings, including risk of blood cancers,
and HSCT has its own risks (including complications related to conditioning and immune effects). Decisions are highly
individualized and typically made with a multidisciplinary team.

Symptom-focused care (AMN and advanced disease)

Many people with AMN or symptomatic adult presentations benefit from supportive care that may include:

• Physical therapy for strength, flexibility, gait, and fall prevention
• Occupational therapy for daily function and adaptive tools
• Medications for spasticity, pain, and bladder symptoms (as appropriate)
• Seizure management if seizures occur
• Speech and swallowing therapy when needed
• Mental health support for patients and caregivers

Diet, supplements, and “Lorenzo’s oil” (the nuanced conversation)

You may hear about dietary fat restriction or “Lorenzo’s oil,” a mixture of unsaturated fatty acids developed to reduce VLCFA
levels. Research suggests it may lower VLCFAs, particularly when started early in asymptomatic individuals, but it is not a
cure and does not reverse established neurologic damage. If someone is considering it, that decision should happen with an
ALD specialist because monitoring and context matter.

Prognosis: why early detection matters so much

ALD outcomes vary widely. Childhood cerebral ALD can progress quickly once inflammatory demyelination accelerates. That’s why
newborn screening and MRI surveillance are emphasized: the goal is to identify cerebral involvement at a stage where targeted
treatment has the best chance to help.

AMN often progresses more slowly, but it can still significantly affect mobility, independence, and quality of life over time.
Adrenal insufficiencywhile seriousis treatable, and early recognition can prevent emergencies.

Living with ALD: practical, real-world strategies

For families of children at risk or diagnosed

• Build a monitoring calendar: MRI dates, endocrine labs, and specialty visits aren’t “extra”they’re prevention.
• School support early: if behavior or learning changes appear, ask about neuropsychological evaluation and accommodations.
• Emergency readiness: if adrenal insufficiency is diagnosed, learn the illness plan and keep emergency medication accessible.

For adults (AMN, symptomatic females, and caregivers)

• Don’t normalize new mobility changes as “just aging” if you have an ABCD1 variantbring them up early.
• Address bladder symptoms proactively; it can dramatically improve daily comfort and confidence.
• Plan for energy management (pacing, mobility aids, and home modifications) before burnout hits.
• Support mental healthuncertainty is stressful, and stress is not a character-building hobby.

Questions to ask your clinician (because Googling at 2 a.m. is exhausting)

• Which ALD phenotype seems most consistent with my (or my child’s) current findings?
• What is our adrenal testing plan, and what symptoms should trigger urgent evaluation?
• What MRI surveillance schedule do you recommend, and what changes would prompt treatment evaluation?
• Are we being seen ator consulting withan ALD specialty center?
• For cerebral disease: are HSCT or gene therapy options appropriate, and what are the risks in our specific situation?
• What therapies can help now (PT/OT, spasticity management, bladder care, mental health resources)?
• Which relatives should be offered testing, and what type of testing is best?

Experiences: what people often describe when ALD enters their lives

Families and adults affected by ALD often describe the experience as two parallel timelines happening at once: the medical
timeline (tests, MRIs, lab values, treatment discussions) and the emotional timeline (shock, denial, guilt, hope, grief,
determinationsometimes all before lunch).

For many parents, the first “something’s off” moment isn’t dramatic. It’s subtle: a child who suddenly struggles with reading
comprehension, a teacher mentioning attention issues, handwriting that gets messier, or behavior that feels out of character.
Because these signs overlap with common childhood challenges, families may spend months chasing explanationsvision tests,
hearing tests, ADHD evaluationsbefore anyone mentions a rare metabolic disorder. When ALD finally becomes part of the
conversation, people often say it feels like the ground shifts: you’re still standing in the same kitchen, but now the world
has different gravity.

Newborn screening can change the storybut it introduces its own kind of stress. Some parents describe it as living with a
“known unknown.” Their child may look perfectly healthy, yet the family is suddenly navigating specialty clinics, endocrine
labs, and MRI schedules. The waiting becomes its own ritual: waiting for the MRI appointment, waiting for results, waiting to
hear whether the scan is “stable.” Many families develop coping systemssmall traditions after appointments, “no medical talk”
rules on certain evenings, or a designated friend who gets the first phone call so parents don’t carry the news alone.

When adrenal insufficiency is diagnosed, people frequently describe a strange mix of fear and relief. Fear, because “hormone
replacement for life” sounds heavy. Relief, because it’s a concrete problem with a concrete solution: take the medication,
learn stress dosing, keep an emergency plan. Over time, many families become highly skilled at adrenal managementalmost like a
second-language fluency in symptoms, dosing, and “when to go in.” It’s not a skill anyone wanted, but it saves lives.

Adults with AMN often describe a slower-burning journey. They notice stiffness in the legs, walking feels less smooth, or they
need more effort to do things they’ve always done. Some feel dismissed initiallytold it’s stress, aging, or “just
deconditioning.” Getting a clear diagnosis can be validating, but it can also raise hard questions about the future. Many
adults talk about adapting in phases: first pacing their day, then adding physical therapy, later considering mobility aids,
and eventually making home changes (handrails, fewer stairs, better lighting to prevent falls). A common theme is that the
right support earlier can preserve independence longer.

Symptomatic females who carry an ABCD1 variant sometimes describe a unique frustration: being told in youth they’re “just a
carrier,” then developing symptoms later and needing to advocate for themselves to be taken seriously. Many say it helps to
track symptoms over timewalking distance, falls, bladder changes, fatigueso clinic visits focus on patterns rather than
impressions.

Across all ALD experiences, community support comes up repeatedly. People often find strength in connecting with others who
understand the vocabularyLoes scores, adrenal testing, MRI intervalswithout needing a 20-minute explanation first. Caregivers
also emphasize the importance of respite and mental health support. ALD can be medically complex, but the day-to-day reality
is human: making school lunches, managing medication schedules, showing up to work, and trying to feel like a person rather
than a calendar reminder.

If there’s one “experience-based” takeaway that shows up again and again, it’s this: ALD is unpredictable, but preparation is
powerful. A monitoring plan, an emergency plan for adrenal issues, and a care team that listens can turn fear into something
more workablelike focus. Not easy. But possible.

Conclusion

Adrenoleukodystrophy is a complex genetic disorder with multiple phenotypesranging from childhood cerebral disease to adult
spinal cord involvement (AMN) and adrenal insufficiency that may appear on its own. Because outcomes are strongly influenced
by timing, the most effective strategy often combines early identification (including newborn screening where
available), regular adrenal testing, and MRI surveillance to spot cerebral changes early.
Targeted options like HSCT or FDA-approved gene therapy may be considered in carefully selected early-stage cases, while
symptom-focused care and adrenal hormone replacement can meaningfully improve safety and quality of life.